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Complete loss of ATM function augments replication
catastrophe induced by ATR inhibition and gemcitabine
in pancreatic cancer models
Charles R. Dunlop 1, Yann Wallez1,2, Timothy Isaac Johnson1, Sandra Bernaldo de Quirós Fernández1, Stephen T. Durant2,
Elaine B. Cadogan2, Alan Lau2, Frances M. Richards1 and Duncan I. Jodrell 1,3
BACKGROUND: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but
validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in
combination with gemcitabine (ATRi/gem), we investigated ATM loss as a predictive biomarker of response to ATRi/gem in PDAC.
METHODS: Through kinase inhibition, siRNA depletion and CRISPR knockout of ATM, we assessed how ATM targeting affected the
sensitivity of PDAC cells to ATRi/gem. Using flow cytometry, immunofluorescence and immunoblotting, we investigated how ATRi/
gem synergise in ATM-proficient and ATM-deficient cells, before assessing the impact of ATM loss on ATRi/gem sensitivity in vivo.
RESULTS: Complete loss of ATM function (through pharmacological inhibition or CRISPR knockout), but not siRNA depletion,
sensitised to ATRi/gem. In ATM-deficient cells, ATRi/gem-induced replication catastrophe was augmented, while phospho-Chk2-T68
and phospho-KAP1-S824 persisted via DNA-PK activity. ATRi/gem caused growth delay in ATM-WT xenografts in NSG mice and
induced regression in ATM-KO xenografts.
CONCLUSIONS: ATM loss augments replication catastrophe-mediated cell death induced by ATRi/gem and may predict clinical
responsiveness to this combination. ATM status should be carefully assessed in tumours from patients with PDAC, since distinction
between ATM-low and ATM-null could be critical in maximising the success of clinical trials using ATM expression as a predictive
biomarker.
British Journal of Cancer (2020) 123:1424–1436; https://doi.org/10.1038/s41416-020-1016-2
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the few major
cancers where overall 5-year survival remains <10%.1 While
surgical resection can be curative, the late emergence of
symptoms means that most patients with PDAC have metastatic
disease at presentation and are ineligible for surgery.2 In the
advanced disease setting, the combination chemotherapy regi-
men FOLFIRINOX (5-FU/leucovorin/irinotecan/oxaliplatin) has
been shown to improve survival, but the median overall survival
for patients with stage IV disease remains <12 months.3 This
highlights the need for better therapeutic approaches. It is hoped
that the rational selection of patients, through precision medicine
approaches, will improve outcomes. However, for personalised
treatment strategies to succeed, careful validation of potential
predictive biomarkers of response is essential.
Recently, we demonstrated that the ataxia telangiectasia and
Rad3-related protein (ATR) kinase inhibitor, AZD6738, synergised
with gemcitabine in PDAC models.4 A key regulator of the DNA
damage response (DDR), ATR is a serine/threonine kinase that
coordinates the replication stress (RS) response. Upon stalling of
a replication fork, ATR acts locally to stabilise the fork and in
addition propagates a global signal throughout the nucleus by
phosphorylating several targets, most notably checkpoint kinase
1 (Chk1).5,6 When active, Chk1 inhibits dormant origin firing to
limit single-stranded DNA (ssDNA) exposure and thus prevents
nuclear exhaustion of RPA.7 Chk1 induces cell cycle arrest by
phosphorylating and inhibiting CDC25 phosphatases.8,9 This
activation of the intra-S checkpoint allows time for attempted
restart of any stalled forks and completion of DNA synthesis in
the RS-affected regions. The antimetabolite gemcitabine has
been used extensively in the treatment of patients with PDAC,
either as a single agent or in combination with nab-paclitaxel. As
a nucleoside analogue, gemcitabine impairs the replication
machinery through multiple mechanisms and induces fork
stalling,10 which activates the ATR/Chk1 axis. We demonstrated
previously that AZD6738 prevents gemcitabine-induced intra-S
checkpoint activation in PDAC cells, leading to an induction
of double-strand break (DSB) markers.4 The combination of
AZD6738 and gemcitabine (ATRi/gem) inhibited growth in a
panel of PDAC cell lines in vitro, while in vivo the combination
induced tumour regression. As a direct result of those studies, a
phase I clinical trial has been launched to assess the safety,
tolerability and preliminary antitumour activity of ATRi/gem in
participants with advanced solid tumours, followed by an
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expansion phase in patients with advanced PDAC (ATRiUM;
NCT03669601).
Being a novel combination, there are no established predictive
biomarkers of response for ATRi/gem. Knowing that ATRi/gem
induces DSBs, we hypothesised that PDAC cells deficient in DDR
pathways would be hypersensitive to the combination. We focussed
our attention on ataxia telangiectasia mutated (ATM), a DDR kinase
that acts as a master regulator of cellular responses to DSBs11,12
which is mutated or lost in a proportion of tumours of many cancer
types, including in PDAC where it is a known susceptibility gene.13
A recent comprehensive literature review of ATM deficiency in PDAC
captured 5234 pancreatic cancer patients and estimated that the
prevalence of germline or somatic ATM mutations in PDAC was
6.4%, though they uncovered a large range of 1–34%.14 In addition,
tissue microarray data sets indicate that low ATM protein expression
in PDAC occurs at around 12–17%,15,16 though there is no consensus
for defining “ATM-low”.
The loss of ATM in a proportion of PDAC samples, plus the central
role it plays in DSB repair, make ATM a primary candidate for a
potential predictive biomarker of response for ATRi/gem therapy.
Loss or mutations in ATM have previously been linked, in some
cancer models, to greater sensitivity to ATRi monotherapy. For
example, primary CLL cells with ATM defects showed enhanced
sensitivity to AZD6738 compared to wild-type (WT) or normal cells17,
and when ATM was knocked down with small interfering RNA
(siRNA) in the gastric adenocarcinoma line, SNU-484, AZD6738 IC50
was reduced ≥2-fold.18 In contrast, when Vendetti et al. used short
hairpin RNAs to deplete ATM in two lung cancer lines, the shATM
cells appeared more resistant to AZD6738 monotherapy than
control—only when AZD6738 was combined with cisplatin did
shATM sensitise.19 In pancreatic cancer models, Ayars et al. reported
that MIA PaCa-2 cells treated with shATM were no more sensitive to
the ATR inhibitor VX-970/VE-822 analogue, VE-821, than control
cells.20 However, work by Perkhofer et al. using mouse models of
ATM-deficient PDAC suggested that ATM loss did confer sensitivity
to VE-822.21
This lack of consistency in the literature between cancer model,
ATR inhibitor used and the experimental method of ATM
depletion employed led us to undertake an assessment of how
ATM status affects ATRi sensitivity in PDAC cells, specifically using
AZD6738 with and without gemcitabine, in alignment with the
ATRiUM trial. By targeting ATM through multiple methods, we
reveal that complete loss of ATM function—through kinase
inhibition or through CRISPR knockout (KO), but not ATM
depletion by RNA interference—sensitises to ATRi and ATRi/gem
in PDAC models. We gained further insight into the mechanisms
by which AZD6738 and gemcitabine synergise to induce cell
death, finding evidence for replication catastrophe (RC) that was
significantly augmented in ATM-deficient cells. Our results suggest
that ATM status should be carefully assessed in tumours from
patients with PDAC and that the distinction between ATM-low and
ATM-null could be crucial in maximising the success of trials using
ATM expression as a predictive biomarker.
METHODS
Cell culture and chemicals
Human cell lines were purchased from ATCC and cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Thermo-
Fisher#41966029) (MIA PaCa-2, PANC-1 and HPAF-II) or RPMI-
1640 (ThermoFisher#21875034) (AsPC-1) plus 10% foetal bovine
serum (FBS; ThermoFisher#10270106). Murine cell lines K8484 and
DT8082 were previously established from KPC mice of 129/SvJae/
C57Bl/6 background in the laboratory of David Tuveson at the
CRUK Cambridge Institute22 and were grown in DMEM with 5%
FBS. Lines were subjected to regular STR fingerprinting and
mycoplasma tests, performed by the CRUK-CI Cell Services core
facility. AZD6738, AZD0156 and AZD7648 were provided by
AstraZeneca. These, plus gemcitabine hydrochloride (Tocris#3259),
were dissolved in dimethyl sulfoxide (DMSO) for in vitro experi-
ments, kept at −20 °C and used within 3 months.
siRNA transfection
ON-TARGETplus-SMARTpool siRNAs targeting ATM were purchased
from Dharmacon (#L-003201-00-0005), as well as a Non-Targeting-
Control-Pool (#D-001810-10-05). Reverse transfection was achieved
using Lipofectamine RNAiMax reagent (Invitrogen#13778/150), as
per the manufacturer’s instructions. Briefly, lipofectamine–siRNA
mixture was incubated in a 100-mm dish, before cells were seeded
on top (final siRNA concentration= 25 nM). Forty-eight hours
later, cells were split and seeded for drug sensitivity assays or
immunoblotting.
CRISPR/Cas9 gene editing
A previously validated all-in-one gRNA-Cas9-GFP plasmid (pAiO-
WT-ATM), the human ATM-specific gRNA sequence, GTTGGTTA-
CATACTTGGACT, cloned into the BbsI site, was kindly provided by
Professor Stephen Jackson of the Wellcome Trust/CRUK Gurdon
Institute, University of Cambridge, UK.23 MIA PaCa-2 forward
transfection was achieved using Lipofectamine 3000 (Invitro-
gen#L3000015) as per the manufacturer’s instructions (6-well
plate). Forty-eight hours post-transfection, cells were split and
single-cell sorted (BD FACS Aria), specifically for the top 3% of
green fluorescent protein (GFP)-positive cells, to enrich for those
positively transfected. Clones were bulked up, before half of each
sample was taken for genomic DNA extraction (QIAamp DNA
Micro Kit #56304). From genomic DNA, the region around the
sgATM-Cas9 target site was amplified by PCR and sent for Sanger
nucleotide sequencing (Eurofins LightRun). Sequencing chroma-
tograms were deconvoluted using the Synthego ICE web tool (ice.
synthego.com). Absence of ATM protein was confirmed by
immunoblotting.
Immunoblotting
Following media removal and a phosphate-buffered saline (PBS)
wash, cell lysis was performed on 60-mm dishes using 50mM Tris
HCl plus 2% sodium dodecyl sulfate (SDS), with phosphatase and
protease inhibitors (Roche#04906837001, Roche#04693159001).
Cells were scraped and boiled at 95 °C for 5 min, before
NanoDrop™ 8000 (A280) protein quantification. Proteins were
resolved using the SDS-polyacrylamide gel electrophoresis gel
system (Life Technologies), detected using IRDye secondary
antibodies (LI-COR) and visualised on the Odyssey CLx imaging
system (LI-COR). Primary antibodies used were obtained from
Abcam (ab) or Cell Signaling Technology (CST), unless otherwise
stated: ATM (ab78), p-ATM-Ser1981 (ab81292), DNA-PKcs
(ab44815), P-DNA-PKcs-Ser2056 (ab18192), KAP1 (ab22553), P-
KAP1-Ser824 (ab133440), RPA32 (ab2175), RAD50 (ab89), p-Chk2-
Thr68 (ab3501), Chk2 (CST3440), p-Rad50-Ser635 (CST14223S),
Chk1 (CST2360), p-Chk1-Ser345 (CST2348), H2AX (CST7631),
β-Actin (CST4970), β-Tubulin (CST2146), Lamin B1 (CST12586),
Vinculin (CST13901), ATR (Santa Cruz Biotechnology#SC-1887), p-
ATR-Thr1989 (Genetex#GTX128145), γH2AX-Ser139 (Millipore#05-
636), p-RPA32-Ser4/8 (Bethyl#A300-245A).
Drug sensitivity assays
Sulforhodamine B (SRB) assays, clonogenic assays and IncuCyte
time-lapse imaging experiments were performed as we have
described previously.4
Flow cytometry
Cells were plated in Corning 60-mm dishes 24 h prior to drug
treatment. After treatment, cells were trypsinised, fixed with ice-
cold 70% EtOH overnight at −20 °C, washed, then resuspended in
0.5 mL of blocking solution (BS) (PBS, 2% BSA, 0.1% Tween-20,
0.1% Triton X100) for 1 h. Finally, cells were treated with 0.5 mL
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FxCycle Violet Stain (Invitrogen #F10347), in BS at 1:1000 dilution,
and run on the BD Biosciences LSRFortessa™ flow cytometer. The
resulting data were analysed using the FlowJo® V10 software.
Quantitative image-based cytometry
Cells were seeded in Corning black flat-bottom 96-well plates 24 h
before drug treatment. After treatment, cells were fixed with 4%
paraformaldehyde for 10 min, permeabilised with 0.1% Triton
X-100, 0.1% Tween-20, and 1×PBS (PBSTT) for 10 min at room
temperature and blocked for 30 min with BS (same as flow).
Primary antibody in BS was added for 1 h at room temperature
(mouse anti-γH2AX S139, Millipore #05-636, 1:2000 and rabbit
anti-phospho-RPA32 S4/8, Bethyl#A300-245A, 1:1000). After wash-
ing, secondary antibody (Alexa Fluor 488 goat anti-rabbit,
Invitrogen#A11034, 1:500 and Alexa Fluor 568 goat anti-mouse,
Invitrogen#A11019, 1:500) plus Hoechst 33342 (Invitrogen#H3570,
1:10,000) in BS was added for 1 h at room temperature.
After washing, images were acquired using the Operetta CLS
High-Content Analysis System (Perkin Elmer), and analysis was
performed using the Harmony 4.5 software.
Fractionation
Fractionation, to derive cytoplasmic and nuclear fractions, was
performed as described by Warren and Eastman.24
Animal experiments
All mouse experiments were carried out in the CRUK-CI BRU, in
accordance with the UK Animals (Scientific Procedures) Act 1986,
with approval from the CRUK-CI Animal Welfare and Ethical
Review Body. Subcutaneous xenografts of MIA PaCa-2 cells were
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Fig. 1 Pharmacological inhibition of ATM sensitises to ATR inhibition in PDAC cell lines. a MIA PaCa-2 were incubated with AZD0156 for
1 h before exposure to 6 Gy of γ-irradiation (IR). Thirty minutes post-IR, cells were harvested for immunoblot analysis. b Human and mouse cell
lines were exposed to AZD0156 for 72 h to generate dose–response curves using the SRB assay. Each point represents the mean ± SEM of
three independent experiments. c, d AZD6738 dose–response curve with and without 30 nM AZD0156, mean ± SEM, n= 3, with GI50 plus 95%
confidence intervals shown. Human (c) and mouse (d) lines were treated for 72 h. e Clonogenic survival of MIA PaCa-2 cells plated at low
density and exposed to the indicated drug combinations for 24 h before washout. Cells were left to grow for 7 days after washout. Each point
represents the mean ± SEM of three independent experiments. The difference between AZD6738 and AZD6738+ 30 nM ATMi was assessed
using multiple t tests. *p ≤ 0.05, **p ≤ 0.01.
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formed by implanting 5 × 106 cells (in 0.2 mL 1:1 Matrigel: PBS) in
the flank of 7–9-week-old female NSG mice (Charles River, 5
mice per cage). Despite some limitations (lack of intratumoural
heterogeneity, absence of immune responses, reduced ability to
recapitulate the tumour microenvironment), subcutaneous xeno-
grafts can offer some advantages over orthotopic models, as
previously reported,25 including ease of use, reproducibility and
earlier tumour detection. Mice with established tumours (average
242mm3) were randomised into treatment groups using the
“spiral” randomisation method (see Supplementary Material).
AZD6738 (AstraZeneca) was dissolved to 5mg/mL in 10% DMSO,
40% propylene glycol and 50% de-ionised sterile water and given
at 50 mg/kg by oral gavage. Gemcitabine (LKT Laboratories, from
Cambridge Bioscience) was dissolved in sterile saline (Vetivex) to
10mg/mL and given at 50mg/kg intraperitoneally (IP). Tumours
were measured twice a week using callipers. Tumour growth
inhibition (TGI)= [MeanVolCtrl−MeanVolTreated/MeanVolCtrl] ×
100. At endpoint, blood was collected by cardiac puncture (under
terminal anaesthesia using isoflurane in accordance with NC3Rs
guidelines) and run on the Mythic 18 haematology analyser as per
instructions (Woodley Equipment Co. Ltd). Mice were killed by
cervical dislocation, confirmed by cutting the femoral artery.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded sections were immunostained
after heat-induced epitope retrieval by sodium citrate at 100 °C for
10–20min, using the Bond Polymer Refine Detection Kit on the
automated Bond system according to the manufacturer’s instruc-
tions (Leica Biosystems). Slides were mounted using Leica CV5030
Coverslipper Workstation and scanned using a ScanScopeXT
(Aperio Technologies). Quantification was performed using the
Halo software (Indica Labs). γH2AX S139 primary antibodies were
CST9718 on human xenograft tissues and ab195190 on mouse
intestine.
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Fig. 2 Deletion of ATM using CRISPR/Cas9, but not protein depletion by siRNA knockdown, sensitises PDAC cells to ATR inhibition. a ATM
protein expression in human cell lines at the start (T0) of the drug sensitivity assay (48 h post-transfection) and at the 72-h assay endpoint
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analysis to determine the ATM status. Clones B4, B7 and C4 were confirmed ATM-null. d AZD6738 dose–response curves of MIA PaCa-2 CRISPR
clones. Assay duration was 72 h. Each point represents the mean ± SEM of three independent experiments.
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RESULTS
Pharmacological inhibition of ATM sensitises to ATR inhibition in
PDAC cell lines
To assess the degree of sensitisation to ATR inhibition associated
with loss of ATM function in PDAC cells, we used the selective and
potent ATM kinase inhibitor, AZD0156,26,27 in combination with
ATR inhibitor AZD6738.28 First, to confirm target engagement, we
assessed the ability of AZD0156 to prevent ATM activation in
PDAC cells. Irradiation (IR) 6 Gy with analysis of P-ATM-S1981 at
0.5–1 h has previously been used by other groups to study ATM
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activation in human cancer cells.27,29–31 In MIA PaCa-2, low
nanomolar concentrations of AZD0156 (≥10 nM) successfully
abrogated IR-induced ATM auto-phosphorylation (Fig. 1a). In
the absence of extrinsic damage, AZD0156 exposure had
minimal effect on human or mouse PDAC cell growth when
used at concentrations ≤100 nM (Fig. 1b), at which off-target
activity is minimised. We next evaluated the degree of growth
inhibition induced by AZD6738 (ATRi) across a range of
AZD0156 (ATMi) concentrations. ATMi 30 nM sensitised all six
of the human (Fig. 1c) and mouse (Fig. 1d) PDAC lines tested to
ATR inhibition. Calculation of Bliss and Loewe synergy scores
using the Combenefit software32 showed that the ATRi/ATMi
combination synergistically inhibited growth in all six of these
lines, albeit modestly in the ATRi-resistant PANC-1 (GI50 > 30 µM;
Fig. S1). To assess the long-term proliferation capacity of cells
exposed to a 24-h pulse of AZD6738, we then performed
clonogenic assays. In this assay, ATMi strikingly sensitised MIA
PaCa-2 to ATRi (Fig. 1e).
ATM protein depletion by siRNA knockdown does not sensitise
PDAC cells to ATR inhibition
Having identified that pharmacological inhibition of ATM in PDAC
cell lines can sensitise to ATRi, we next evaluated the potential for
siRNA knockdown of ATM to confer ATRi sensitivity in three
human cell lines—MIA PaCa-2, HPAF-II and PANC-1. Despite
achieving durable ATM knockdown (88% mean knockdown
efficiency across the 3 lines, SD ±7%) (Fig. 2a), this did not
significantly sensitise any of the 3 cell lines to 72-h exposure to
AZD6738 (Fig. 2b). Due to this disparity between kinase
inactivation (ATMi) and protein depletion (siATM), we hypothe-
sised that reduced expression of ATM may be insufficient to
sensitise cells to AZD6738.
Deletion of ATM using CRISPR/Cas9 does significantly sensitise
PDAC cells to ATR inhibition
Having observed a sensitisation effect with the ATMi, but not with
siATM, we next used CRISPR/Cas9 technology to generate ATM KO
MIA PaCa-2 single-cell clones. By Sanger sequencing (Fig. S2A) and
immunoblotting, we identified three clones that did not express
detectable ATM and showed no phospho-ATM S1981 upon IR
(Fig. 2c). These three ATM-null clones were sevenfold more
sensitive to AZD6738 than WT MIA PaCa-2 cells (mean ATM-null
cells GI50= 0.37 µM; mean ATM-positive cells GI50= 2.73 µM;
Figs. 2d and S2B). As sensitisation occurred upon ATM KO, but
not knockdown with siRNA, this suggests that complete loss of
ATM function, not just depletion, is necessary to sensitise PDAC
cells to ATRi monotherapy.
ATM loss of function sensitises to the combination of AZD6738
and gemcitabine
We next tested whether reduced ATM function could sensitise to
the combination of AZD6738 and gemcitabine (ATRi/gem). Kinase
inhibition of ATM conferred sensitivity to 72-h ATRi/gem exposure
in MIA PaCa-2 (Fig. 3a) but siRNA depletion did not (Fig. 3b).
Meanwhile, genetic deletion of ATM caused a 2.6-fold shift in the
mean gemcitabine GI50 (Fig. S2B, C) and made MIA PaCa-2
cells hypersensitive to ATRi/gem (Fig. 3c). This was particularly
evident in assays where the ATRi/gem was pulsed for 24 h with
observation of subsequent cell growth by time-lapse imaging.
A 24-h pulse of 500 nM AZD6738 and 10 nM gemcitabine had no
effect on the growth ability of the WT line (growth as percentage
of solvent control= 96% ± 7) but maintained durable growth
inhibition for at least 4 days in the ATM-KO cells (growth as
percentage of solvent control= 7% ± 1) (Fig. 3d, e), with a parallel
increase in cell death, quantified by YoYo-3 staining (Fig. 3d).
The impressive sensitivity of the isogenic ATM-KO cells to the
combination of AZD6738 and gemcitabine provides evidence that
complete ATM loss could be a predictive biomarker of response to
ATRi/gem in patients with PDAC.
ATRi/gem-induced DDR activation persists in the absence of ATM
function due to DNA-PK activity
Having found that targeting ATM, by either pharmacological
inhibition or by genetic deletion, can sensitise PDAC cells to the
combination of AZD6738 and gemcitabine, we next investigated
the DDR signalling pathways activated by ATRi/gem, in the
presence or absence of ATM function. Twenty-four-hour exposure
of MIA PaCa-2 cells to 2000 nM ATRi and 30 nM gemcitabine
(concentrations known to be synergistic in this line4) induced
phosphorylation of ATM and its downstream targets RAD50, KAP1
and Chk2 (Fig. 4a). Perhaps paradoxically (since they are reported
to be ATM targets), phospho-ATM S1981, phospho-KAP1 S824 and
phospho-Chk2 T68 all persisted even in the presence of ATMi
(AZD0156) (Fig. 4a). This persistence was specific to ATRi/gem,
since IR-induced activation of these markers was prevented by
10 nM ATMi (Figs. 1a and 4a). This is similar to our previous
findings, when we found that the ATRi/gem combination induced
P-Chk2 and P-KAP1 to a similar extent in siATM cells as in siCTRL
cells.4 Here, in the ATRi/gem treated samples, we did observe
ATMi dose-dependent abrogation of phospho-RAD50 S635
(Fig. 4a), a biomarker of ATM activity,33,34 suggesting that the
ATMi was acting on target. Therefore, the persistence of phospho-
Chk2 T68 and others could be due to the activity of another
kinase, the most likely candidate being DNA-PK. Indeed, in both
MIA PaCa-2 (Fig. 4b) and HPAF-II (Fig. 4c), the phospho-KAP1 and
phospho-Chk2 induced by ATRi or ATRi/gem treatment was
abrogated by the selective DNA-PK inhibitor, AZD7648.35 Along
with phospho-ATM, these phosphorylations were only fully
prevented upon combined ATMi and DNA-PKi. We also probed
for ATR and its downstream partner Chk1. Gemcitabine-induced
phospho-ATR T1989 persisted in the presence of ATRi due to ATM-
dependent phosphorylation (Fig. 4b). Meanwhile, phospho-Chk1
S345 was only abrogated upon DNA-PK inhibition (Fig. 4b, c). Thus
we revealed that much of the downstream DDR activation
Fig. 3 ATM loss of function sensitises to the combination of AZD6738 and gemcitabine. a The effect of ATM kinase inhibition by AZD0156
on ATRi (AZD6738) and gemcitabine sensitivity in MIA PaCa-2. b The effect of ATM depletion by siRNA on AZD6738 and gemcitabine
sensitivity in MIA PaCa-2. c The effect of ATM deletion by CRISPR/Cas9 on AZD6738 and gemcitabine sensitivity in MIA PaCa-2. In all three
panels (a–c), MIA PaCa-2 in the conditions listed were treated with increasing concentrations of AZD6738 and gemcitabine for 72 h. Left=
matrices display growth as percentage of solvent control (as assessed by SRB assay), mean ± SD, n= 3. Right= AZD6738 dose–response
curves in the presence of 1 or 10 nM gemcitabine, mean ± SEM, n= 3. d MIA PaCa-2 WT and MIA PaCa-2 ATM-KO (clone B7) cells in medium
containing the YOYO-3 iodide cell-impermeant dye were treated with AZD6738 and gemcitabine in a 6 × 8 concentration grid for 24 h (grey
bar denotes period of drug treatment). The drugs were washed out and replaced with fresh YOYO-3-containing medium. Three fields per
sample were imaged by IncuCyte time-lapse microscopy every 3 h for 4 days post-washout. Phase Object Confluence was quantified as the
percentage of the image area occupied by cells (left). Cell death accumulation (right) was quantified by measuring Red Object Confluence,
and expressed as a percentage of the total Object Confluence. Each curve is a representative of three independent experiments. e The same
cells from the IncuCyte experiment in d were fixed in TCA 4 days post-washout and the relative growth was assessed by SRB assay. Left=
growth as percentage of solvent control, mean ± SD, n= 3 independent experiments. Right= Combenefit synergy score (Loewe).
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induced by ATRi or ATRi/gem was not prevented by ATMi (besides
phospho-RAD50 and phospho-ATR) because of phosphorylation
by DNA-PK.
We next interrogated DDR pathway activation in ATM-KO MIA
PaCa-2 cells. Once again, ATRi/gem treatment upregulated phos-
pho-Chk2, phospho-KAP1 and phospho-Chk1 in both the presence
and absence of ATM function (Fig. 4d). These phosphorylations were
DNA-PK driven, as evidenced by their abrogation by AZD7648
(Fig. 4d). The low baseline levels of phospho-RAD50 S635 in
untreated ATM-KO MIA PaCa-2 cells appeared to be ATR dependent,
consistent with recent findings that in ATM-deficient models ATR
can phosphorylate RAD50.34 Unlike with Chk2 and KAP1, the ability
for the ATM-KO cells to upregulate phospho-RAD50 S635 upon
ATRi/gem was significantly impaired in comparison to ATM-WT. The
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modest phospho-RAD50 S635 that was induced by ATRi/gem was
DNA-PK dependent (Fig. 4d). Meanwhile, phosphorylation of ATR
T1989 appeared to be ATR and ATM dependent but not DNA-PK
dependent (Fig. 4d).
Despite the contribution of DNA-PK to many of the DDR
phosphorylations in ATRi-treated cells, Bliss and Loewe cytotoxi-
city synergy scores showed consistently less synergy for the
AZD6738 and AZD7648 (DNA-PKi) combination than for AZD6738
and AZD0156 (ATMi) across human and mouse PDAC cell lines
(Figs. 4e, f and S3A). Furthermore, in triple combination SRB
experiments, the addition of DNA-PKi to ATRi/gem led to only
moderate sensitisation compared to ATMi (Figs. 4g, h and S3D).
This suggests that ATM function is more critical to cell survival
during ATRi or ATRi/gem exposure than DNA-PK activity. It also
implies that the Chk1/Chk2 phosphorylations that arise through
DNA-PK activity do not play a major protective role in ATRi/gem-
exposed PDAC cells.
ATRi/gem-induced RC is augmented in ATM-null PDAC cells
We next investigated the effect of AZD6738 and gemcitabine
treatment on the cell cycle profile of ATM-proficient and ATM-
deficient PDAC cells. Treatment with 500 nM AZD6738 and 10 nM
gemcitabine for 24 h had little-to-no effect on the cell cycle profile
of WT MIA PaCa-2 cells. Conversely, 10 nM gemcitabine induced
significant intra-S accumulation in the ATM-KO MIA PaCa-2, along
with a reduction in the G2-M proportion (Fig. 5a). This was
augmented by the addition of 500 nM AZD6738, which also
increased the sub-G1 fraction, indicating induction of cell death.
When the higher concentration of 2000 nM AZD6738 was used,
we observed modest intra-S accumulation with ATRi monother-
apy, which was specific to the ATM-null cells, while addition of
30 nM gemcitabine could induce S-phase arrest in both the ATM-
WT and ATM-KO cells (Fig. S4A).
Through immunoblotting, we had found that ATRi/gem
treatment induced DNA-PK-driven activation of the checkpoint
proteins, Chk1 and Chk2. However, co-treating with the DNA-PKi
AZD7648 did not alter the cell cycle profiles in any of the ATRi/
gem conditions (Fig. S4A), indicating that the intra-S-phase arrests
we observed were independent of checkpoint activation. An
alternative reason for the intra-S accumulation, independent of a
checkpoint, could be induction of RC. This is defined as the
widespread breakage of multiple replication forks, resulting from
a global exhaustion of RPA and subsequent degradation of
unprotected ssDNA at stalled forks.7,24,36 We found that 500 nM
AZD6738 and 10 nM gemcitabine caused RPA32 to deplete from
the cytosol and accumulate in the nucleus over time, with a
parallel increase in nuclear γH2AX S139, in the ATM-KO MIA PaCa-
2 (Fig. 5b). Next, using quantitative image-based cytometry,
we assessed the degree of RC induced by ATRi and ATRi/gem in
ATM-WT vs ATM-KO, by quantifying the emergence of cells with
pan-nuclear γH2AX S139 and pan-nuclear phospho-RPA32 S4/8
(Figs. 5c and S4B). After 24-h exposure to 500 nM AZD6738 alone,
just 1.4% of WT MIA PaCa-2 cells were pan-nuclear for
both markers, compared to 8.7% of ATM-KO cells (Fig. 5d).
The combination of 500 nM AZD6738 and 10 nM gemcitabine
induced pan-nuclear γH2AX S139 and phospho-RPA32 in both
cell types but much more extensively in the ATM-KO cells
(9.9% WT double positive vs 58.2% ATM-KO double positive after
24 h; Fig. 5e). Hoechst quantification confirmed that the majority
of the cells with pan-nuclear damage had DNA contents between
2n and 4n, consistent with S-phase failure (Fig. S4C). Our
observation of increased RC in the ATM-KO cells suggests that
ATM protects against nuclear-wide fork collapse during ATRi/gem
treatment.
AZD6738 monotherapy causes growth delay in ATM-deficient
PDAC xenografts, while combined treatment with gemcitabine
induces regression
Next, we assessed the efficacy of AZD6738 monotherapy in vivo.
We treated NSG mice bearing either MIA PaCa-2 WT or MIA PaCa-2
ATM-KO subcutaneous xenografts, with 50 mg/kg AZD6738 (oral
gavage, once daily, 5 consecutive days a week) for 3 weeks. No
efficacy was seen in the ATM-proficient model, whereas in the
ATM-KO tumours we observed a 61% TGI after 3 weeks of
treatment (Fig. 6a). Subsequently, we assessed whether we could
use low-dose gemcitabine as a sensitiser to AZD6738, to perhaps
improve on the already impressive response seen with ATRi alone
in the ATM-KO model. Regression is rare in MIA PaCa-2 xenograft
studies, but adding gemcitabine (50 mg/kg, IP, once per week) to
the 50mg/kg AZD6738 schedule induced regression in the ATM-
KO MIA PaCa-2 tumours (mean volume change after 3 weeks=
−17.8%, 95% confidence interval −2.7% to −32.8%) and growth
delay in the WT tumours (46% TGI) (Figs. 6b and S5A). As expected
with this xenograft model, no metastases were identified in any
group. The dose schedules used were well tolerated such that,
across the two studies, just two mice experienced notable weight
loss—one in the gemcitabine-alone group (1/17) and one in the
ATRi/gem group (1/17) (Fig. S5B). Endpoint blood cell counts
showed no significant difference between the ATRi/gem combi-
nation group and gemcitabine single agent (Fig. S5C).
IHC quantification of γH2AX percentage of positive nuclei in the
tumours, fixed 6 h after the final dose, revealed an increase in the
ATRi/gem groups compared to vehicle; mean γH2AX positivity
increased from 5.7 to 11.4% in WT tumours with ATRi/gem (p <
0.01) and from 7.3 to 15.4% in ATM-KO tumours with ATRi/gem
compared to vehicle (p < 0.0001) (Figs. 6d and S5D). γH2AX
positivity was higher in the ATM-KO tumours following ATRi/gem
treatment compared to the ATM-WT (p < 0.05). In both sets of
Fig. 4 ATRi/gem-induced DDR activation persists in the absence of ATM function due to DNA-PK activity. a Immunoblot analysis of MIA
PaCa-2 cells. Cells that received 6 Gy of γ-irradiation (IR) were harvested 30min post-IR. All other samples were harvested after 24 h of drug
exposure. ATRi+ GEM denotes 2 µM AZD6738 and 30 nM gemcitabine. ATMi is AZD0156 and was either applied concurrently with ATRi/gem
or administered 1 h prior to IR in the case of the two IR samples. b Immunoblot analysis of MIA PaCa-2 cells. Cells were harvested after 24 h of
drug exposure. ATRi is AZD6738, ATMi is AZD0156, DNA-PKi is AZD7648. c Immunoblot analysis of HPAF-II cells. Cells were harvested after 24 h
of drug exposure. d Immunoblot analysis of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO cells (clone B7). Cells were harvested after 24 h of drug
exposure. e Cells were treated with increasing concentrations of ATRi (AZD6738) and DNA-PKi (AZD7648) for 72 h, and growth was assessed
by SRB assay. Top= growth as percentage of solvent control. Bottom= Combenefit synergy score (Loewe). Data, mean ± SD, n= 3. For
matrices of all cell lines, see Fig. S3A. f Synergy comparison of the AZD6738 and AZD0156 combination (ATRi+ ATMi, see Fig. S1) vs the
AZD6738 and AZD7648 combination (ATRi+DNAPKi, Fig. S3A). Cells were treated with increasing concentrations for 72 h and growth as
percentage of solvent control was assessed by SRB assay. Combenefit software was used to calculate the sum of synergy and antagonism
across the dose ranges tested. g The effect of DNA-PK inhibition on AZD6783 and gemcitabine sensitivity in MIA PaCa-2. Values denote
growth as percentage of solvent control (as assessed by SRB assay), mean ± SD, n= 3. h Visualisation of how much more effect ATM inhibition
has compared to DNA-PK inhibition on the growth of ATRi/gem-treated MIAPaCa-2. Left= the %Control values of the MIA PaCa-2+ 1 µM
DNA-PKi matrix from Fig. 4g were subtracted from those of the MIA PaCa-2+DMSO matrix from Fig. 4g. Right= the %Control values of the
MIA PaCa-2+ 30 nM ATMi matrix from Fig. 3a were subtracted from those of the MIA PaCa-2+DMSO matrix from Fig. 3a.
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tumours, the γH2AX positivity persisted for at least 24 h after
dosing (Fig. 6d). Meanwhile, in the small intestine, the high γH2AX
induced at 6 h by gemcitabine or ATRi/gem did not persist
(Fig. 6e), indicative of DNA repair in normal tissue.
DISCUSSION
The application of precision medicine strategies, where thera-
pies are assigned based on patient-specific tumour vulnerabil-
ities, has the potential to improve outcomes for diseases such as
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PDAC. Having launched a phase I trial to assess the combination
of AZD6738 and gemcitabine (ATRiUM, NCT03669601), we
sought to investigate the potential utility of ATM loss as a
predictive biomarker of response for ATRi/gem in PDAC. ATM
and ATR have been reported to share a synthetic lethal
relationship in some cancer types.17–19,37,38 However, it has
become increasingly clear that most synthetic lethal interactions
depend highly on the genetic background in which they are
studied.39 By targeting ATM through multiple methods, our data
indicate that complete loss of ATM function is necessary to
sensitise PDAC cells to AZD6738 or the AZD6738 and
gemcitabine combination. This has important implications, as
it brings into question how best to assess ATM status in future
clinical trials.
A recent example of a trial where ATM status was assessed is
Study 39 (NCT01063517). This was a phase II efficacy study
assessing the combination of olaparib and paclitaxel in gastric
cancer patients, which identified a greater overall survival
benefit in patients with “ATM-low” tumours.40 Here “ATM-low”
tumours were defined as those with ≤10% ATM tumour cell
nuclear staining, quantified by an IHC test using the ATM (Y170)
antibody clone. In the follow-up phase III GOLD trial
(NCT01924533), a new IHC reporter assay was developed that
used the same antibody clone but with different assay
configurations and reagents.41 The cut-off for “ATM-low”
tumours was redefined as <25% of ATM tumour cell nuclear
staining (to account for increased sensitivity of new assay);
however, this trial failed to meet its primary endpoint and failed
to confirm the survival benefit in “ATM-low” patients that had
been observed previously.42 It remains unclear whether
redefining the cut-off to a lower threshold would bring a
different result. In relation to ATRi/gem in PDAC, our data would
support the use of complete ATM loss (i.e. 0% ATM tumour cell
nuclear staining), as opposed to <10 or 25% staining, since only
ATM-null cells appeared to be hypersensitive. This leads to the
question of how to identify ATM-null tumours in a clinical
setting. Such tumour samples have been identified previously,
including in the very first phase I dose escalation trial of an
ATR inhibitor, which identified a colorectal cancer patient with
100% ATM loss by IHC, who showed a complete response (19+
months) to M660 monotherapy.43,44 Evaluating ATM function-
ality by IHC, using markers such as phospho-ATM and phospho-
RAD50,34 in conjunction with total ATM could add further depth
to ATM status assessments; however, this would likely require
patients to be challenged with a DSB-inducing agent prior to
biopsy to be most informative. The presence of germline or
somatic ATM mutations, combined with a low IHC score, would
add confidence that a patient’s tumour is indeed ATM negative,
thus incorporating next-generation sequencing (NGS) in parallel
with IHC could improve clinical biomarker assessments.45 On the
whole, if precision medicine techniques are to be implemented
successfully, it is becoming increasingly apparent that the field
will have to be more precise and detailed in the characterisation
of patients and their tumours, and multi-modal assessments of
patient samples may facilitate this.
As well as the important distinction between ATM-low and
ATM-null, our data also reveal further insight into the mechanism
of how AZD6738 and gemcitabine synergise to induce cell death.
The increase in nuclear RPA over time upon ATRi/gem exposure,
plus the accumulation of S-phase cells pan-nuclear for DNA
damage and replication stress markers, suggests that the
combination induces RC (Fig. 5). During this catastrophic fork
collapse, Chk1 and Chk2 are phosphorylated by DNA-PK, but the
lack of clear ATRi/DNAPKi synergy and the inability for DNA-PKi to
significantly potentiate ATRi/gem (Fig. 4g), suggests that these
DNA-PK-driven signals may be bystander events during RC. The
fact that ATM-deficient cells are hypersensitive to ATRi/gem-
induced RC indicates that ATM plays a critical role in protecting
against this widespread fork collapse. A recent study found that
topotecan- or olaparib-induced breakage of replication forks is
lethal in ATM-deficient models due to the induction of toxic non-
homologous end joining (NHEJ).23 Their data suggested that the
toxic NHEJ was mediated by XRCC4 and ligase IV, but not DNA-PK.
Here we found that DNA-PKi did not significantly potentiate nor
attenuate the effect of ATRi/gem in WT or ATM-KO cells. Going
forward, it will be interesting to interrogate whether the
hypersensitivity of ATM-null PDAC cells to ATRi/gem is also due
to toxic NHEJ.
Minimising toxicity is a major challenge when combining
DDRi and chemotherapy in the clinic. Most phase I trials of this
type are designed such that the DNA-damaging cytotoxic is
administered at its standard-of-care dose—i.e. at the expected
maximum tolerated dose—and the DDRi is titrated at increasing
levels. As a result, any increase in toxicity will immediately
become dose limiting and the true potential of these combina-
tions may not be fully explored. The ATRiUM trial design is
unique, in that it is using a model-based approach to guide dose
escalation, starting each drug at dosages that are <100% of the
predicted or actual single-agent dose. In essence, the aim is to
use the gemcitabine as a sensitiser to AZD6738, rather than
simply administering the cytotoxic at its typical maximum
dosage. In the preclinical study reported here, we demonstrated
that this strategy can indeed be effective, particularly in an ATM-
deficient setting. We first found that 50 mg/kg AZD6738
monotherapy, once daily for 5 consecutive days a week, induced
significant growth delay in the ATM-null tumours. Rather than
introduce gemcitabine at its typical preclinical single-agent dose
of 100 mg/kg twice per week,46 we used a comparatively low
gemcitabine dose of 50 mg/kg, once per week, to allow
pharmacodynamically effective dose schedules of AZD6738.
This regimen induced growth delay in the ATM-WT and tumour
regression in the ATM-KO tumours (Fig. 6b), thus demonstrating
proof of principle that low-dose gemcitabine can be used as a
sensitiser to AZD6738 in vivo.
As well as assessing the safety, tolerability and preliminary
antitumour activity of ATRi/gem in a novel model-based approach,
Fig. 5 ATRi/gem-induced replication catastrophe is augmented in ATM-null PDAC cells. a DNA content of MIA PaCa-2 WT and MIA PaCa-2
ATM-KO (clone B7) cells following 24-h exposure of the indicated drugs. Left= representative DNA content histograms, x= FxCycle Violet
fluorescence (DNA content), y= cell count. Right= cell cycle distribution. Each bar represents the mean ± SD of three independent
experiments. A one-way ANOVA analysis, comparing the percentage of S-phase fractions, was performed with Tukey’s multiple comparisons
tests, *p ≤ 0.05, ***p ≤ 0.001. b Immunoblot analysis of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO cells treated as indicated, separated by
cytosolic and nuclear fractions. c Representative images showing the pan-nuclear emergence of γH2AX S139 and phospho-RPA32 S4/8 upon
24-h exposure to 500 nM AZD6738 and 10 nM gemcitabine. The images shown were acquired using a ×10 objective lens. Images acquired
using a ×20 objective lens are displayed in Fig. S4B. d, e Quantitative image-based cytometry to determine the proportion of cells pan-nuclear
for both γH2AX S139 and phospho-RPA32 S4/8, at the time points indicated. ATRi= 500 nM AZD6738. GEM= 10 nM gemcitabine. Images
were acquired using the Operetta CLS High-Content Analysis System (×10 objective) and analysis was performed using the Harmony
4.5 software. The resulting data were imported into FlowJo as CSV files to generate the pseudo-colour plots shown. Percentages of double-
positive cells are shown.
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the ATRiUM trial is incorporating IHC assessment of baseline ATM,
NGS of patient DNA and on-treatment biopsies. This will enable
some of the conclusions we have made in this study to be
scrutinised clinically. This could steer the design of future
precision medicine-based trials that will examine the promise
that ATM shows as a predictive biomarker of response for
AZD6738 and gemcitabine combination therapy in PDAC.
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induces regression. a Tumour volumes of MIA PaCa-2 WT and MIA PaCa-2 ATM-KO (clone B7) xenografts in NSG mice, with AZD6738
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